India’s indigenous coronavirus vaccine ‘Covaxin’ shows robust immune response in its first phase clinical trials

India’s indigenous coronavirus vaccine ‘Covaxin’ shows robust immune response in its first phase clinical trials


Representative picture

Indigenous Indian coronavirus vaccine Covaxin has shown in its first clinical studies to produce a robust immune response.

A detailed immunogenicity response from the first phase of the vaccine trial was declared by the manufacturers. Covaxin, which was jointly developed by Bharat Biotech and ICMR from Hyderabad, has proven to be safe according to the results of the first clinical trial phase and has not caused any serious side effects in people of any dose group. The ICMR has announced that the vaccine can be stored at temperatures of 2 and 8 degrees Celsius, which also makes it compatible with the National Immunization Plan.

Covaxin is one of three coronavirus vaccine candidates being considered by the drug agency in India for approval for emergency use. It is currently in the third and final phase of clinical trials with nearly 26,000 volunteers in the 18 and 55 age bracket.

Source